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ABSTRACT
Carbonic anhydrase XII (CAXII) is a membrane enzyme that maintains pH 
homeostasis and sustains optimum P-glycoprotein (Pgp) efflux activity in cancer 
cells. Here, we investigated a panel of eight CAXII inhibitors (compounds 1–8), 
for their potential to reverse Pgp mediated tumor cell chemoresistance. Inhibitors  
(5 nM) were screened in human and murine cancer cells (colon, lung, breast, bone) 
with different expression levels of CAXII and Pgp. We identified three CAXII inhibitors 
(compounds 1, 2 and 4) that significantly (≥ 2 fold) increased the intracellular 
retention of the Pgp-substrate and chemotherapeutic doxorubicin, and restored its 
cytotoxic activity. The inhibitors lowered intracellular pH to indirectly impair Pgp 
activity. Ca12-knockout assays confirmed that the chemosensitizing property of the 
compounds was dependent on active CAXII. Furthermore, in a preclinical model of 
drug-resistant breast tumors compound 1 (1900 ng/kg) restored the efficacy of 
doxorubicin to the same extent as the direct Pgp inhibitor tariquidar. The expression 
of carbonic anhydrase IX had no effect on the intracellular doxorubicin accumulation. 
Our work provides strong evidence that CAXII inhibitors are effective chemosensitizer 
agents in CAXII-positive and Pgp-positive cancer cells. The use of CAXII inhibitors 
may represent a turning point in combinatorial chemotherapeutic schemes to treat 
multidrug-resistant tumors.
INTRODUCTION
Carbonic anhydrases (CA, EC 4.2.1.1) are highly 
conserved and ubiquitous zinc metalloenzymes that 
reversibly hydrate carbon dioxide to bicarbonate and a 
proton: CO2 + H2O D HCO3− + H+, controlling intracellular 
pH (pHi) [1]. CAIX and CAXII, two integral membrane 
proteins with the catalytic domain on the extracellular side, 
are overexpressed in many solid and hypoxic tumors [2–5]. 
Given the expression prevalence of CAXII in transformed 
cells, high levels of tissue-associated and circulating 
CAXII have been proposed as predictive markers of 
thyroid [6] and squamous lung [7] cancers, respectively. 
CAXII overexpression has also been associated with poor 
prognosis in human gliomas [8], oral squamous cancer 
[9] and esophageal squamous cell cancer [10]. In cancer 
cells CAXII contributes to extracellular acidification while 
also maintaining a normal intracellular pH (pHi). CAXII 
hydrates tumor cell generating CO2. As a consequence H
+ 
ions are trapped extracellularly, lowering pH outside the 
cell (pHo), while HCO3
- is taken up by the cell to buffer the 
intracellular pH (pHi). [11, 12]. In healthy tissues CAXII 
is expressed mainly in the kidney and large intestine, 
with minimal expression in other tissues. The acid-base 
equilibrium regulated by CAXII is associated with Na+ and 
Cl− transport that in turn drives passive water absorption in 
these organs [2, 13].
The inhibition of CAXII has been associated 
with impaired tumor growth, with a CAXII-inhibitory 
monoclonal antibody showing significant antitumor 
properties in mouse xenografts of breast cancer [14]. 
There is no corresponding study to correlate effects of 
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small molecule CAXII inhibition with CAXII expression 
in tumors, however CAXII inhibitors have demonstrated 
antimetastatic activity in a breast cancer xenograft [15]. 
We recently demonstrated that CAXII is 
overexpressed in chemoresistant cancer cells expressing 
the drug efflux transporter P-glycoprotein (Pgp) [16]. Pgp 
recognizes multiple substrates, including a broad range 
of chemotherapeutics. Pgp expression in cancer cells 
contributes to multidrug resistance (MDR) [17, 18]. CAXII 
physically interacts with Pgp and it has been proposed that 
CAXII maintains the optimal pH for Pgp efflux activity, 
thus potentiating the contribution of Pgp to MDR [13].
Given the correlation of CAXII activity with tumor 
proliferation, invasion and chemoresistance, the interest 
in developing selective inhibitors of CAXII has increased 
in recent years, however in vitro and in vivo studies with 
small molecule CAXII inhibitors that directly link the 
mechanism of action to CAXII inhibition remain scarce 
and CAXII is much less studied than the other cancer-
associated CA, CAIX. 
The aim of this study is to evaluate CAXII 
inhibitors as selective chemosensitizers in MDR tumor 
models. Eight test inhibitors with variable CA inhibition 
profiles and variable physicochemical properties were 
selected to establish the potential of CAXII inhibitors to 
indirectly inhibit Pgp activity to resensitize MDR cells 
to doxorubicin. We show that CAXII inhibitors have 
very good chemosensitizing efficacy, and increase the 
effectiveness of the chemotherapeutic drug doxorubicin 
up to 4.4-fold. This correlated with high expression of 
both CAXII and Pgp in vitro and in vivo. Our results 
demonstrate that small molecule CAXII inhibitors may 
have future applications in clinical settings, for example, 
by allowing a reduction in the dosage of cytotoxic drugs 
or To restore the cytotoxic efficacy of existing drugs that 
have lost their effectiveness i.e. resensitizing of hard-to-
treat tumors to chemotherapeutics.
RESULTS
Selective CAXII inhibitors increase doxorubicin 
accumulation and cytotoxicity in CAXII-positive 
and Pgp-positive cancer cells
The CA inhibition, CAXII selectivity and cLog 
P values for inhibitors 1–8 (Figure 1) are given in Table 1. 
On the basis of the Ki values for 1, 2 and 4–8 at 
CAXII (Ki < 10 nM), all the compounds were evaluated 
at 5 nM concentrations in the following in vitro assays. 
In these experimental conditions, compounds 1, 2 and 
4 increased the intracellular accumulation of doxorubicin, 
a Pgp substrate, in cells with high expression of both 
CAXII and Pgp (Supplementary Figure S1), such as 
HT29/DX, A549/DX, MDA-MB-231, TUBO, JC, U2OS/
DX and SaOS/DX cells (Figure 2A–2J). The compounds 
had no effect on cells with detectable levels of just one of 
these two proteins expressed (Supplementary Figure S1), 
such as HT29, A549, MCF7, SKBR3, T74D, U2OS and 
SaOS cells (Figure 2A–2J). The expression of CAIX 
did not influence the effects of the compounds on the 
intracellular doxorubicin accumulation in all cell lines 
tested. Compound 3 (CAXII Ki = 96 nM) has low activity 
as a CAXII inhibitor, however was included in the 
study as it is a prodrug of compound 2, an active CAXII 
inhibitor (CAXII Ki = 7.3 nM). Consequently compounds 
2 and 3 provide a ‘drug/prodrug’ pair where the observed 
activity of the ‘drug’ may be predominantly attributed 
to 2. Compounds 1, 2 and 4 were the most consistently 
effective at increasing the intracellular accumulation of 
doxorubicin across all CAXII-positive and Pgp-positive 
cell lines tested, showing the same potency as the 
direct Pgp inhibitor, tariquidar (Figure 2A–2J). The 
compounds also increased the intracellular retention 
of the chemotherapeutics vinblastine (Supplementary 
Figure S2A) and paclitaxel (Supplementary Figure S2B), 
two Pgp substrates with different Pgp binding sites [19]. 
Compounds 1, 2 and 4 were selected for the follow-up 
assays, described next. 
In accordance with the correlation of CAXII 
expression and cancer cell proliferation [14], compounds 
1, 2 and 4 reduced the viability of CAXII-positive cell 
lines. The reduction in viability for individual compounds 
was: ≤ 31 ± 6% in HT29/DX cells, ≤ 28 ± 10% in A549 
cells, ≤ 38 ± 7% in A549/DX cells, ≤ 33 ± 12% in T74D 
cells, ≤ 36 ± 11% in MDA-MB-231 cells, ≤ 28 ± 7% in 
TUBO cells, ≤ 30 ± 10% in JC cells, ≤ 27 ± 8% in U2OS/
DX cells, ≤ 32 ± 7% in SaOS/DX cells (p < 0.05 for all 
cell lines; n = 4). In contrast, the compounds were devoid 
of any effects on viability in cells with low or undetectable 
levels of CAXII, including HT29, MCF7, SKBR3, U2OS, 
SaOS cell lines (not shown). As expected, doxorubicin 
reduced viability in cells with undetectable or low levels 
of Pgp, i.e. HT29, A549, MCF7, SKBR3, T74D, U2OS 
and SaOS cells; in these doxorubicin-sensitive cell lines 
the compounds did not exert additive effects on viability 
compared to doxorubicin treatment alone (not shown). In 
contrast, HT29/DX, A549/DX, MDA-MB-231, TUBO, 
JC, U2OS/DX, SaOS/DX cells, which are positive 
for both Pgp and CAXII (Supplementary Figure S1), 
were unresponsive to doxorubicin alone not shown. 
Compounds 1, 2 and 4 restored doxorubicin efficacy 
and further reduced cell viability. The differences in cell 
viability between cells treated with compounds alone and 
cells co-treated with compounds plus doxorubicin were: 
≥ 38 ± 6% in HT29/DX cells, ≥ 22 ± 8% in A549 cells, 
≥ 38 ± 7% in A549/DX cells, ≥ 18 ± 7% in T74D cells, 
≥ 34 ± 10% in MDA-MB-231 cells, ≥ 22 ± 8% in TUBO 
cells, ≥ 29 ± 8% in JC cells, ≥ 27 ± 9% in U2OS/DX 
cells, ≥ 27 ± 7% in SaOS/DX cells, (p < 0.05; n = 4). 
These differences suggest that the decreased viability of 
cells co-treated with CAXII inhibitors and doxorubicin 
was due to the increased doxorubicin accumulation with 
added compound 1, 2 or 4 and/or to a synergistic effect 
of compound 1, 2 or 4 and doxorubicin, rather than to 
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cytotoxicity exerted by the CAXII inhibitors themselves. 
Accordingly, the doxorubicin IC50 was significantly 
reduced by the co-treatment with the CAXII inhibitors in 
these cell lines. Co-treatment with compounds 1, 2 and 4 
had the same efficacy as treatment with tariquidar (Figure 
3A–3J) in resensitizing cells to doxorubicin (Table 2). 
Notably, in CAXII-negative MCF7 and SKBR3 cells 
that overexpress Pgp (Supplementary Figure S3A), the 
compounds did not increase the intracellular retention 
of doxorubicin (Supplementary Figure S3B). Lastly, 
compounds 1, 2 and 4 did not exert any cytotoxic 
effect (Supplementary Figure S4B) in not-transformed 
human epithelial colon CCD-Co-18 cells, epithelial 
lung BEAS-2B cells, epithelial breast MCF10A cells 
or fibroblasts that do not have detectable levels of 
CAXII (Supplementary Figure S4A). Collectively 
these results demonstrate that compounds 1, 2 and 4 are 
cytotoxic agents against CAXII-positive cancer cells and 
substantially reverse doxorubicin resistance in cancer 
cells expressing both CAXII and Pgp, but are without 
significant cytotoxicity in CAXII-negative and not-
transformed cells. 
Table 1: Inhibition data (Ki) of human CA isozymes I, II, IX and XII, CAXII selectivity and cLog 
P values of compounds 1–8 and the established CA inhibitor acetazolamide (AZA)
Compd cLog Pa
Ki (nM)b CAXII Isozyme Selectivity
c
CA I CA II CA IX CA XII CA I/XII CAII/ XII CA IX/XII
1 
2 
−2.65 9000
1180
5.0
82
2.0
8.6
1.0
7.3
9000 5.0 2.0
−3.30 161 11.2 1.2
3 +1.40 3360 105 77 96 35 1.1 0.8
4 −3.30 4500 93 62 7.6 592 12.2 8.2
5 −3.17 102 9.1 95 8.3 12.3 1.1 11.5
6 −3.17 87 7.8 99 8.7 10 0.9 11.4
7 −4.94 107 5.0 106 8.9 12.0 0.6 11.9
8 −4.94 101 4.8 98 8.2 12.3 0.6 12.0
AZA −1.00 250 12 25 5.7 43.9 2.1 4.4
aCalculated using ChemDraw Ultra 12 or InstantJChem 3.0.4 from ChemAxon. bErrors in the range of ± 5% of the 
reported value, from three determinations. cSelectivity is determined by the ratio of Kis for CA isozyme relative to CAXII. 
Nonstandard abbreviations: cLog P (calculated Log P partician coefficient of the compound between octanol and water), Ki 
(inhibition constant).
Figure 1: Chemical structure of CAXII inhibitors.
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Figure 2: Effects of CAXII inhibitors on intracellular doxorubicin retention in drug-sensitive and drug-resistant cancer 
cells. Human doxorubicin-sensitive colon cancer HT29 cells and their resistant counterpart HT29/DX cells (panel A), human doxorubicin-
sensitive lung cancer A549 cells and their resistant counterpart A549/DX cells (panel B), human doxorubicin-sensitive and resistant breast 
cancer MCF7 (panel C), SKBR3 (panel D), T74D (panel E) and MDA-MB-231 cells (panel F), murine doxorubicin-resistant TUBO (panel G) 
and JC cells (panel H), human doxorubicin-sensitive osteosarcoma U2OS cells and their resistant counterpart U2OS/DX cells (panel I), 
human doxorubicin-sensitive osteosarcoma Saos and their resistant counterpart SaOS/DX (panel J) were grown for 24 h in the presence 
of 5 μM doxorubicin, alone (–) or in the presence of 5 nM of compounds 1–8. Tariquidar (25 nM; Tar) was included as Pgp inhibitor. The 
intracellular drug content was measured fluorimetrically. Data are presented as means ± SD (n = 4). Versus doxorubicin alone (–): *p < 0.05; 
for cells treated with compounds 1–8 or tariquidar, doxorubicin-resistant cells versus the corresponding doxorubicin-sensitive cells: °p < 0.05.
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Figure 3: Effects of CAXII inhibitors on viability of drug-sensitive and drug-resistant cancer cells. Human doxorubicin-
sensitive colon cancer HT29 cells and their resistant counterpart HT29/DX cells (panel A), human doxorubicin-sensitive lung cancer A549 
cells and their resistant counterpart A549/DX cells (panel B), human doxorubicin-sensitive and resistant breast cancer MCF7 (panel C), 
SKBR3 (panel D), T74D (panel E) and MDA-MB-231 cells (panel F), murine doxorubicin-resistant TUBO (panel G) and JC cells (panel H), 
human doxorubicin-sensitive osteosarcoma U2OS cells and their resistant counterpart U2OS/DX cells (panel I), human doxorubicin-
sensitive osteosarcoma Saos and their resistant counterpart SaOS/DX (panel J) were incubated for 72 h with increasing concentrations 
(1 nM – 1 mM) of doxorubicin (dox), alone or in the presence of 5 nM of compound 1, 2 and 4, then stained in quadruplicate with neutral 
red. Tariquidar (25 nM; Tar) was included as a Pgp inhibitor. IC50 of tariquidar alone was > 10 µM; at 25 nM tariquidar reduced viability 
≤ 8.23 ± 1.44 % in each cell line. Data are presented as mean IC50 ± SD (n = 4). HT29/DX, A549/DX, U2OS/DX, SaOS/DX versus HT29, 
A549, U2OS, SaOS cells: *p < 0.001; versus doxorubicin alone: °p < 0.005.
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Selective CAXII inhibitors lower Pgp ATPase 
activity and alter intracellular pH
CAXII and Pgp proteins co-immunoprecipitated 
(Figure 4A) in HT29/DX, A549/DX, MDA-MB-231, 
TUBO, JC, U2OS/DX and SaOS/DX cells, which express 
both CAXII and Pgp (Supplementary Figure S1), as well 
as in Pgp-enriched vesicles derived from the membranes of 
these cells (Supplementary Figure S5), indicating that these 
two enzymes were physically associated in the cell plasma 
membrane. Treatment of these doxorubicin-resistant cell 
lines with CAXII inhibitors 1, 2 and 4 (5 nM) lowered the 
pHi relative to untreated cells: compound 1 (CAXII Ki = 
1.0 nM) reduced pHi ≥ 0.24 units, compound 2 (CAXII = 
Ki 7.3 nM) reduced pHi ≥ 0.12 units, compound 4 (CAXII 
= Ki 7.6 nM) reduced pHi ≥ 0.06 units (Supplementary 
Figure S6). Isolated Pgp has consistent basal activity 
across the pH range 6.2 to 7.6 (at 37 °C) [16], this range 
encompasses the pHi of the resistant cancer cell lines tested 
(Supplementary Figure S6). Notably, the reduction of pHi 
exerted by compounds 1, 2 and 4 (Supplementary Figure 
S6) was paralleled by a modest, but significant reduction 
(≥ 1.47-fold) of Pgp ATPase activity (Figure 4B). 
The compounds also reduced the substrate-dependent 
activation of Pgp, as demonstrated by the ATPase assays 
performed in the presence of Pgp substrate doxorubicin 
(Supplementary Figure S7). In contrast, in the presence 
of the Pgp inhibitor tariquidar, which strongly decreased 
ATPase activity, there was no further reduction of ATPase 
activity by co-treatment of tariquidar with compounds 1, 2 
and 4 (Supplementary Figure S7). 
Knockout of ca12 abrogates the effects of CAXII 
inhibitors on doxorubicin accumulation and 
cytotoxicity
To confirm that the chemosensitizing effect of 
compounds 1, 2 and 4 was dependent on CAXII activity, 
we knocked-out ca12 in a selection of the CAXII-positive 
and Pgp-positive cell lines: HT29/DX, A549/DX, MDA-
MB-231 and U2OS/DX cells (Figure 5A). Compounds 1, 
2 and 4 lost the ability to further increase the doxorubicin 
intracellular accumulation (Figure 5B) in ca12 knocked-
out (KO) cells, to resensitize the cell lines to doxorubicin-
induced cytotoxicity (Figure 5C) and to inhibit Pgp 
activity (Supplementary Figure S8). These results are 
consistent with the attribution of the effect of compounds 
1, 2 and 4 as being dependent on the modulation of CAXII 
activity. Ca12 KO cells had lower pHi (Figure 6A) and 
lower Pgp activity (Figure 6B) than wild-type cells. The 
addition of the Na+/H+ ionophore monensin (10 µM) 
increased the pHi of ca12 KO cells (Figure 6A) and the 
Pgp activity (Figure 6B) to values comparable with wild-
type cells. Distinct from wild-type cells, doxorubicin 
did not increase the activity of Pgp in ca12 KO cells 
(Supplementary Figure S8), suggesting that the absence 
of CAXII hampered the substrate-dependent activation of 
Pgp. In contrast, tariquidar inhibited Pgp activity in both 
Table 2: Resistance factor (Rf) of cell lines treated with doxorubicin alone or doxorubicin in the 
presence of compounds 1, 2 and 4, versus cells treated with doxorubicin plus tariquidar
Cell line Rf dox Rf dox + 1 Rf dox + 2 Rf dox + 4
HT29 1.39 1.07 1.35 1.23
HT29/DX 4.26 1.66 1.91 1.52
A549 1.31 1.21 1.08 1.09
A549/DX 4.45 1.59 1.46 1.57
MCF7 1.32 1.18 1.25 1.14
SKBR3 2.19 2.25 2.14 1.97
T74D 0.98 0.92 0.96 0.88
MDA-MB-231 4.55 1.34 1.25 1.37
TUBO 4.23 1.33 1.64 1.41
JC 7.61 1.23 1.29 1.54
U2OS 1.05 1.14 1.02 0.99
U2OS/DX 15.44 2.02 1.31 1.76
SaOS 1.43 1.47 1.36 1.18
SaOS/DX 14.97 1.32 1.26 1.42
Cells were incubated for 72 h with increasing concentrations (1 nM–1 mM) of doxorubicin (dox), alone or in the presence of 
5 nM of compound 1, 2 and 4, then stained in quadruplicate with neutral red. Tariquidar (25 nM, for 24 h; Tar) was included 
as Pgp inhibitor (n = 4). Rf (resistance factor) was calculated as the ratio between mean IC50 in cells treated with compound 
1, 2 and 4, and mean IC50 in cells treated with doxorubicin and tarquidar.
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wild-type and ca12 KO cells (Supplementary Figure S8). 
These findings suggest that the absence or presence of 
CAXII does not influence the efficacy of tariquidar.
CAXII inhibition reduces the growth of 
doxorubicin-resistant tumors in vivo
To test the efficacy of CAXII inhibition in 
preclinical models of breast resistant tumors, we focused 
our attention on compound 1, as it had achieved the 
most striking effect in terms of CAXII inhibition and 
doxorubicin-chemosensitizing effects in vitro. 
We used the highly chemoresistant JC breast tumor 
model, which is refractory to doxorubicin (Figure 7A–7B). 
To maximize the drug delivery to the tumor, we injected 
compound 1 intratumorally, at 10 nM (19 ng/kg) and 
1 μM (1900 ng/kg). The lower concentration falls in the 
range of the CAXII in vitro inhibition of compound 1 (Ki = 
1.0 nM); the higher concentration was selected to mitigate 
compound 1 clearance through lymphatic and blood 
vessels. Compound 1 has low mouse plasma stability 
(t1/2 = 0.7 h) but good mouse liver microsome stability 
(t1/2 = 134.8 min). At both dosages compound 1 had no 
effect on tumor growth when used alone, but when co-
Figure 4: Effects of compound 1, 2 and 4 on Pgp activity. (A) Biotinylated plasma membrane-derived extracts from HT29/
DX, A549/DX, MDA-MB-231, TUBO, JC, U2OS/DX and SaOS/DX cells were immunoprecipitated (IP) with anti-Pgp antibody, then 
immunoblotted (IB) with anti-CAXII or anti-Pgp antibodies. Pancadherin level was used as control of equal protein loading. no Ab: A549/
DX sample immunoprecipitated without antibody. The figure is representative of one out of three experiments with similar results. (B) Cells 
were grown for 24 h in fresh medium (–) or in medium containing 5 nM compounds 1, 2 and 4. The Pgp ATPase activity was measured 
spectrophotometrically on Pgp-rich vesicles extracted from membrane fractions. Data are presented as means ± SD (n = 3). For all cell 
lines, versus untreated cells (–): *p < 0.002.
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Figure 5: Effects of compound 1, 2 and 4 in ca12KO cancer cells. (A) HT29/DX, A549/DX, MDA-MB-231 and U2OS/DX cells 
were left untreated (–), treated with a not-targeting scrambled (scr) vector or with a ca12-targeting vector (KOCAXII), then immunoblotted 
for CAXII or CAIX. HT29, A549, MCF, U2OS cells were used as control of cells with low or undetectable levels of CAXII. β-tubulin 
level was used as control of equal protein loading. The figure is representative of one out of three experiments with similar results. (B) 
Cells treated as in A were incubated for 24 h with 5 μM doxorubicin (–), alone or in the presence of 5 nM compounds 1, 2 or 4, then the 
intracellular drug content was measured fluorimetrically. Data are presented as means ± SD (n = 4). For all cell lines, versus scr cells 
incubated with doxorubicin alone (–): *p < 0.001. (C) Cells were incubated for 72 h in fresh medium (–), or in medium containing 5 μM 
doxorubicin (dox), 5 nM compounds 1, 2 or 4, alone or in combination, then stained with neutral red dye. The absorbance of viable cells 
was measured spectrophotometrically. Data are presented as means ± SD (n = 4). For all cell lines, versus scr untreated cells (–): *p < 0.01.
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administered with doxorubicin it significantly increased the 
anti-proliferative effect of doxorubicin with 21% and 47% 
reduction in tumor volume at day 18, when used at 19 ng/
kg and 1900 ng/kg, respectively (Figure 7A–7B). At 1900 
ng/kg compound 1 produced tumor reduction similar 
to tariquidar (Figure 7A–7B). Worthy of note, at both 
dosages compound 1 did not induce liver, kidney or heart 
toxicity, according to the hematochemical parameters 
of the animals at the time of sacrifice (Supplementary 
Table S1). As expected, doxorubicin increased creatine 
phosphokinase (CPK) level, an index of cardiac damage, 
but compound 1 did not further increase this parameter in 
doxorubicin-treated animals (Supplementary Table S1). 
DISCUSSION
In this work, we assessed a panel of CAXII 
inhibitors for their capacity to reverse doxorubicin 
resistance in MDR cancer cells that overexpress Pgp and 
resensitize cells to doxorubicin.
Our group has previously designed and synthesized 
carbohydrate-based CA inhibitors to preferentially inhibit 
Figure 6: Effects of pHi rescue on Pgp activity of ca12 KO cells. HT29/DX, A549/DX, MDA-MB-231 and U2OS/DX cells 
were treated with a not-targeting scrambled (scr) vector or with a ca12-targeting vector (KO). (A) Cells were grown in fresh medium (–) 
or treated with monensin (10 µM for 3 h; mon). pHi measurement was performed by flow cytometry. Data are presented as means ± SD 
(n = 4). For all cell lines, versus untreated scr cells (–): *p < 0.005; vs KO cells: °p < 0.002. (B) The Pgp ATPase activity was measured 
spectrophotometrically on Pgp-rich vesicles extracted from membrane fractions of cells incubated as reported in A. Data are presented as 
means ± SD (n = 3). For all cell lines, versus untreated scr cells (–): * p < 0.001; vs KO cells: °p < 0.001.
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cancer-associated CA isozymes (CAIX and CAXII) 
over intracellular CAs [12, 20, 21]. The combination of 
enzyme inhibition and physicochemical properties of the 
inhibitors was optimized to reduce passive membrane 
diffusion and favour selective inhibition of extracellular 
CAs over intracellular CAs. For this study a panel of eight 
compounds, 1–8, were selected. The cLog P value of a 
compound is indicative of passive membrane permeability, 
with cLog P values < 0 expected to give compounds with 
minimal passive cell membrane permeability. Compounds 
with strong CAXII inhibition, with CAXII selectivity, 
and with cLog P values < 0 are thus predicted to inhibit 
extracellular CA enzymes over intracellular CA enzymes 
and perform best in the cell-based models. The selection of 
compounds for this study was guided by these parameters.
Compounds 1, 2 and 4–8 all have Ki < 10 nM 
for CAXII. These compounds also incorporate a polar 
monosaccharide or disaccharide moiety such that cLog 
P values are in the range −3.17 to −4.94. Compound 3 
(cLog P + 1.40) is an acyl ester prodrug of compound 2, 
unlike 2 it is expected that 3 will enter cells by passive 
membrane diffusion and then be converted to 2 by 
intracellular esterases. Consequently compounds 2 and 3 
provide a ‘drug/prodrug’ pair where the observed activity 
of the ‘drug’ may be attributed to extracellular (2) and 
intracellular (3) localization of the inhibitor, respectively.
Compounds 1, 2 and 4 increased doxorubicin 
accumulation and efficacy in cancer cells that co-express 
CAXII and Pgp, with the same efficacy of tariquidar, one 
of the strongest third-generation Pgp inhibitors known 
[22], used in phase I and phase II clinical trials (https://
clinicaltrials.gov). The compounds also increased the 
intracellular accumulation of vinblastine and paclitaxel, 
Pgp substrates with alternate Pgp binding sites to 
doxorubicin [19]. This suggests that the CAXII inhibitors 
reduce Pgp activity, in a non-Pgp substrate specific manner. 
Additionally, doxorubicin and vinblastine are weakly 
basic drugs with increased protonation at acidic pH, while 
paclitaxel is a non-ionizable drug that remains neutral 
at acidic pH, hence the resensitizing effect of CAXII 
inhibitors is not limited to protonatable Pgp substrates. 
Furthermore, this effect was observed in tumor cells of 
different histological origins and species, suggesting that 
the compounds activity is independent of tumor type, 
species type or Pgp substrate type, requiring only a CAXII 
positive and Pgp positive phenotype. This phenotype may 
identify chemoresistant tumors that represent the best 
candidates for the co-treatment of Pgp substrate cancer 
chemotherapeutics with CAXII inhibitors. Since CAXII 
is usually poorly expressed in most healthy cells [5], the 
use of CAXII inhibitors, may provide a selective tumor-
targeting approach when administered with standard 
Figure 7: In vivo efficacy of compound 1 and doxorubicin against drug-resistant breast tumors. (A) Six week-old 
female BALB/c mice were inoculated s.c. with 1 × 106 JC cells. When the tumor reached the volume of 100 mm3 (day 7), the mice were 
randomized into 8 groups (10 animals/group) and treated on days 0, 6 and 12 after the randomization as it follows: 1) control group, treated 
with 0.1 ml saline solution intravenously (i.v.); 2) doxorubicin group, treated with 5 mg/kg doxorubicin i.v.; 3) tariquidar group, treated 
with 5 mg/kg tariquidar per os; 4) C1 19 group, treated with 19 ng/kg compound 1 (in 0.1 ml saline solution; final concentration: 10 nM) 
intratumorally; 5) C1 1900 group, treated with 1900 ng/kg compound 1 (in 0.1 ml saline solution; final concentration: 1 µM) intratumorally; 
6) doxorubicin + tariquidar group, treated with 5 mg/kg doxorubicin i.v. and 5 mg/kg tariquidar per os; 7) doxorubicin + C1 19 group, 
treated with 5 mg/kg doxorubicin i.v. and 19 ng/kg compound 1 intratumorally; 8) doxorubicin + C1 1900 group, treated with 5 mg/kg 
doxorubicin i.v. and 1900 ng/kg compound 1 intratumorally. Tumor growth was monitored by caliper measure. Data are presented as means 
± SD. Dox +Tar/dox + C1 19/dox + C1 1900 groups versus ctrl group: *p < 0.05; dox + Tar/dox + C1 0.5/dox + C1 50 groups versus dox 
group: °p < 0.005. (B) Photographs of representative tumors from each treatment group after mice sacrifice.
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chemotherapeutic drugs to patients with drug resistant 
tumors. Indeed, our compounds were not cytotoxic in 
epithelial and fibroblasts cells, that had undetectable levels 
of CAXII. The lack of efficacy of compounds 1, 2 and 4 
in ca12 KO cancer cells further demonstrated that CAXII 
inhibition is the critical mechanism of action in reversing 
doxorubicin resistance. Similarly, the lack of efficacy of 
the compounds in CAXII-negative cells overexpressing 
Pgp suggests that the increased doxorubicin retention is 
not due to a direct inhibition of Pgp, but it is a consequence 
of CAXII inhibition. 
CAIX has been correlated with an aggressive tumor 
phenotype [5, 11] and resistance against doxorubicin 
in breast cancer tumors [23]. However, in our in vitro 
screening the efficacy of compounds 1, 2 and 4 in 
increasing doxorubicin accumulation and cytotoxicity was 
independent of the expression of CAIX. These findings 
correlate with previous data that demonstrated silencing 
of CAIX in doxorubicin-resistant cells did not impact on 
drug-resistance, while silencing of CAXII reversed the 
drug-resistant phenotype [16]. 
CAXII is critical for maintaining normal pHi in 
cancer cells [1, 11]. We hypothesize that the inhibition 
of CAXII alters the membrane microenvironment where 
Pgp works, impairing the optimal conditions for its 
function as an efflux pump. Chemoresistant cells have a 
slightly alkaline pHi that contributes to the maintenance 
of their drug-resistant phenotype [24]. Isolated Pgp has 
consistent basal activity across the pH range 6.2 to 7.6 
(at 37°C) [25], which is compatible with the pHi of the 
doxorubicin-resistant cells analyzed (ranging from 7.45 to 
7.64 pH units). We previously reported that the treatment 
with the classical CAXII inhibitor acetazolamide 
(AZA), as well as CAXII silencing, lowered the pHi of 
doxorubicin-resistant colon cancer cells and reduced 
Pgp activity [16]. Compounds 1, 2 and 4 decreased pHi 
(1 by 0.24 units, 2 by 0.12 units, and 4 by 0.06 units). 
Similarly ca12 KO cells had lower pHi than wild-type 
cells. This decrease was paralleled by a reduction in Pgp 
ATPase activity. Of note, when pHi in ca12 KO cells was 
increased to the same pH value of wild-type cells with 
monensin, Pgp activity also increased. These results 
suggest that the increased pHi maintained by CAXII in 
resistant cells is critical to maintain optimal Pgp activity. 
The lower pHi produced by CAXII inhibition reduces Pgp 
activity, resulting in increased intracellular retention of 
doxorubicin, vinblastine and paclitaxel. Although we did 
not measure the pH within the lipid microenvironment 
where Pgp and CAXII operate in close proximity, we may 
infer that the inhibition of CAXII reduced the pH in the 
plasma membrane microenvironment even more than in 
whole cell, markedly decreasing Pgp activity. Notably, 
compounds 1, 2 and 4 are all expected to have low cell 
membrane passive diffusion and thus inhibit CAXII. 
By contrast, compound 3, a lipophilic ester ‘prodrug’ of 
2 and expected to yield compound 2 in the intracellular 
environment following esterase processing, was devoid of 
efficacy. These data further suggest that it is inhibition of 
extracellular facing CAXII (and not intracellular CAs) that 
may be attributed to the reversal of drug resistance.
Compared with the classical CAXII inhibitor AZA, 
compounds 1, 2 and 4 offer the advantage of higher 
selectivity toward CAXII, lower Ki values and reduced 
lipophilicity. These attributes render them promising 
candidates to be tested in vivo, using the Pgp-positive 
and doxorubicin-resistant JC model [26, 27]. We selected 
compound 1 for an in vivo study as this compound had the 
maximal chemosensitizing effect in vitro. 
To avoid compound related metabolism or 
clearance and maximise tumor delivery, we administered 
1 intratumorally. Either a dosage of 1 around the 
CAXII Ki or a 100-fold higher dosage, to counteract 
compound clearance through lymphatic and blood 
vessels, significantly reduced tumor growth when co-
administered with doxorubicin. Since the compound 
alone (i.e. without co-administration of doxorubicin) did 
not reduce tumor growth, such effect was likely due to 
the increased retention of doxorubicin within cancer cells. 
These data suggest that compound 1 effectively reverses 
the resistance to doxorubicin in vivo to resensitize these 
resistant cells to doxorubicin treatment. The sensitization 
efficacy was comparable to the third-generation Pgp 
inhibitor tariquidar. Moreover, compound 1, either alone 
or with doxorubicin, did not elicit liver or kidney toxicity, 
or increase the cardiac damage induced by doxorubicin 
(an anthracycline), according to the hematochemical 
parameters of the animals. We propose that the indirect 
mechanism of action of CAXII inhibitors to reduce Pgp 
activity voids the usual in vivo toxicity associated with 
direct Pgp inhibition. Additionally, as CA inhibitors have 
been a mainstay of human clinical intervention for several 
decades (more than 25 clinically approved CA inhibitors) 
this drug class has a recorded safety profile [28]. Moreover, 
mammalian CAs belong to the α-CA family, with murine 
CAXII expressed in the large intestine and kidney 
similarly to human CAXII [29, 30]. Given the significant 
chemosensitizing effect of compound 1, we speculate 
that the dosage of doxorubicin- if co-administered with 
compound 1 (or other selective small molecule CAXII 
inhibitors) -may even be reduced while retaining its 
antitumor efficacy yet limiting doxorubicin associated 
cardiotoxicity.
In summary, our work suggests that CAXII 
inhibitors are potent chemosensitizing agents in tumors 
overexpressing both CAXII and Pgp. Given the prevalent 
expression of CAXII in tumor tissues and the high 
selectivity of our inhibitors towards this CA isoform, 
our compounds appear as promising tumor-selective 
agents. These results may be a turning point toward new 
treatments based on a combination of a CAXII selective 
inhibitor with chemotherapeutic drugs, where the 
chemotherapeutic drugs alone are ineffective in treating 
Pgp-positive (i.e. MDR) tumors. This approach may be 
particularly beneficial for patients with tumors that co-
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express CAXII and Pgp, a typical feature of aggressive 
and chemoresistant tumors. Furthermore, neo-adjuvant 
protocols based on anthracyclines are currently used in the 
treatment of breast cancer to improve patient outcomes, 
with the purpose to reduce tumor mass and allow a more 
conservative surgery [31]. In a translational perspective 
our study may provide the rational basis for a new neo-
adjuvant combinatorial therapy for breast tumors to 
enhance the effectiveness of cytotoxic chemotherapeutic 
drugs, i.e. the loco-regional administration of a CAXII 
inhibitor as a chemosensitizer agent followed by 
systemic administration of doxorubicin. To the best of 
our knowledge, such an approach has not been reported. 
The expression of CAIX, the more well studied cancer-
associated CA isozyme, did not influence the effects of the 
compounds on the intracellular doxorubicin accumulation 
in all cell lines tested. We recommend that future studies 
involving CAs in cancer concomitantly examine CAIX 
and CAXII expression, rather than only CAIX, to better 
inform the interpretation of experimental findings.
MATERIALS AND METHODS
Materials
The plasticware for cell cultures was obtained 
from Falcon (Becton Dickinson, Franklin Lakes, NJ). 
The electrophoresis reagents were obtained from Bio-
Rad Laboratories (Hercules, CA). The protein content 
of cell lysates was assessed with the BCA kit from 
Sigma Chemicals Co. (St. Louis, MO). Tariquidar 
dihydrochloride was from Tocris Bioscience (Bristol, UK). 
Unless specified otherwise, all reagents were purchased 
from Sigma Chemicals Co.
CAXII inhibitors
The synthesis and structural characterization 
of carbohydrate-based sulfamates (1–4) [32, 33] and 
sulfonamides (5–8) [12] has been fully described 
previously by us. The chemical structure of the compounds 
is reported in Figure 1.
CA inhibition
The inhibition of CA I, II, IX and XII by test 
inhibitors (1–8) has been previously reported by us [12, 32, 
33]. Inhibition data and isozyme selectivity values are 
reported in Table 1. Briefly, a stopped-flow instrument was 
used to monitor the CA-catalyzed CO2 hydration reaction 
for a period of 10–100 s with phenol red as a pH indicator. 
Saturated CO2 solutions in water at 20°C were used as 
substrate, while the recombinant CA protein was prepared in 
Hepes buffer (10 mM, pH 7.5) with added NaClO4 (0.1 M) 
to maintain a constant the ionic strength. The inhibitor 
and enzyme solutions were preincubated for 15 min at 
room temperature prior to assay in order to allow for the 
formation of the enzyme-inhibitor complex. The inhibition 
constants were obtained by nonlinear least-squares methods 
using PRISM 3. The curve fitting algorithm allowed us to 
obtain the IC50 values, from which Ki values were calculated 
by using the Cheng-Prusoff equation.
Cell lines
Human colon cancer HT29 cells, lung cancer A549 
cells, breast cancer MCF-7, SKBR3, T74D and MDA-
MB-231 cells, osteosarcoma U2OS and SaOS cells, 
murine chemoresistant JC cells, not-transformed human 
colon epithelial CCD-Co-18 cells, lung epithelial BEAS-
2B cells, breast epithelial MCF10A cells were purchased 
from ATCC (Manassas, VA). Murine chemoresistant 
TUBO cells were a kind gift of Prof. Federica Cavallo, 
Department of Molecular Biotechnology and Health 
Sciences, University of Torino, Italy. Not-transformed 
human fibroblasts were a kind gift of Prof. Franco Novelli, 
Department of Molecular Biotechnology and Health 
Sciences, University of Torino, Italy. Human HT29/DX 
and A549/DX were generated by stepwise selection in 
medium with increasing concentration of doxorubicin, 
as reported by us [34], and maintained in culture 
medium with a final concentration of 200 nM and 100 
nM doxorubicin, respectively. U2OS/DX and SaOS/DX 
cells were generated with a similar procedure [35] and 
maintained in culture medium with a final concentration 
of 1 μM doxorubicin. The expression levels of CAXII, 
CAIX and Pgp were measured by immunoblotting (see 
below): the results are reported in the Supplementary 
Figure S1. All cell lines were authenticated by 
microsatellite analysis, using the PowerPlex kit (Promega 
Corporation, Madison, WI; last authentication: June 
2016). Cells were maintained in media supplemented 
with 10% v/v fetal bovine serum, 1% v/v penicillin-
streptomycin, 1% v/v L-glutamine.
Immunoblotting
For whole cell lysates, the cells were rinsed with 
ice-cold lysis buffer (50 mM, Tris, 10 mM EDTA, 1% v/v 
Triton-X100), supplemented with the protease inhibitor 
cocktail set III (80 μM aprotinin, 5 mM bestatin, 1.5 mM 
leupeptin, 1 mM pepstatin; Calbiochem, San Diego, CA), 
2 mM phenylmethylsulfonyl fluoride and 1 mM Na3VO4, 
then sonicated and centrifuged at 13,000× g for 10 min at 
4oC. 20 μg protein extracts were subjected to SDS-PAGE 
and probed with the following antibodies: anti-CAXII 
(Abcam, Cambridge, UK), anti-CAIX (Novus Biologicals, 
Littleton, CO), anti-Pgp (C219, Calbiochem), anti-β-
tubulin (Santa Cruz Biotechnology Inc., Santa Cruz, CA), 
followed by a peroxidase-conjugated secondary antibody 
(Bio-Rad Laboratories). The membranes were washed 
with Tris-buffered saline-Tween 0.1% v/v solution, and the 
proteins were detected by enhanced chemiluminescence 
(Bio-Rad Laboratories). Plasma membrane-associated 
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proteins were evaluated in biotinylation assays, using the 
Cell Surface Protein isolation kit (Thermo Fisher Scientific 
Inc., Waltham, MA), as previously reported [36]. An 
anti-pancadherin antibody (Santa Cruz Biotechnology 
Inc.) was used to confirm equal protein loading. In co-
immunoprecipitation experiments, 100 μg of plasma 
membrane-associated proteins were immunoprecipitated 
with the anti-Pgp antibody, using the PureProteome protein 
A and protein G Magnetic Beads (Millipore, Billerica, MA). 
The immunoprecipitated proteins were separated by SDS-
PAGE and probed with anti-CAXII or anti-Pgp antibodies, 
followed by a peroxidase-conjugated secondary antibody.
Pgp overexpression
To generate the Pgp-positive MCF7 and SKBR3 
cells, the pHa vector containing the complete mdr1 
cDNA was purchased from Addgene (Cambridge, MA) 
and subcloned into pCDNA3 vector (Invitrogen Life 
Technologies, Milan, Italy) as described [37].
Chemotherapeutic drug accumulation
Doxorubicin content was measured fluorimetrically 
as detailed previously by us [34]. Vinblastine and 
paclitaxel accumulation were measured by labelling 
cells with 1 µCi [3H]-vinblastine sulphate (PerkinElmer, 
Waltham, MA) and [3H]-paclitaxel (Moravek Inc., Brea, 
CA). Cells were washed twice with PBS, detached with 
trypsin and sonicated. The intracellular drug content 
was measured by liquid scintillation. The results were 
expressed as nmol drug/mg cell proteins, according to 
titration curves previously set. 
Cell viability
Cell viability was evaluated by measuring the 
percentage of cells stained with neutral red dye, as 
reported previously [38]. The viability of untreated 
cells was considered 100%; the results were expressed 
as percentage of viable cells in each experimental 
condition versus untreated cells. To determine the IC50 of 
doxorubicin in CAXII inhibitor treated cells 5 × 105 cells, 
with concentrations of doxorubicin (ranging from 1 nM 
to 1 mM), were incubated in the absence or presence of 
5 nM of each CAXII inhibitor for 72 h. The inhibitory 
concentration 50 (IC50) is defined as the concentration of 
doxorubicin that kills 50% of cells. The resistance factor 
(Rf) was calculated as the ratio between mean IC50 in 
cells treated with CAXII inhibitors and mean IC50 in cells 
treated with tarquidar.
Pgp ATPase activity
The assay was performed on Pgp-enriched membrane 
vesicles as detailed in [39]. Verapamil (10 µM) was added 
to the reaction mix to achieve a maximal activation of 
the Pgp ATPase activity. Results were expressed as nmol 
hydrolyzed phosphate (Pi)/min/mg proteins, according to 
the titration curve previously prepared.
pHi measurement
pHi was measured by incubating whole cells 
with 5 µM 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-
carboxyfluorescein acetoxymethyl ester for 15 min at 
37°C and reading the intracellular fluorescence by a 
FACSCalibur flow cytometer (Becton Dickinson). The 
intracellular fluorescence was converted into pH units 
according to a titration curve, as described previously [24].
Ca12 knockout
5 × 105 cells were transduced with 1 μg RNA vector 
(CRISPR pCas guide vector) ca12 or 1 μg not-targeting 
vector, mixed with 1 μg donor DNA vector (Origene, 
Rockville, MD), following the manufacturer’s instructions. 
Stable KO cells were selected in complete medium 
containing 1 μg/ml puromycin for three weeks. Knockout 
efficacy was evaluated by immunoblotting, as reported 
above. Cell viability was evaluated by neutral red staining: 
ca12 KO cells had the same viability than parental cells 
(data not shown).
In vivo tumor growth
To evaluate the anti-tumor efficacy of CAXII 
inhibitors, we injected subcutaneously 1 × 106 JC cells, a 
mammary cancer cell line known for its high expression 
of Pgp [26] and its strong refractoriness to doxorubicin 
[27], mixed with 100 µL Matrigel, in syngeneic 6 week-
old female BALB/c mice (weight: 20 g ± 1.3; Charles 
River Laboratories Italia, Calco). Animals were housed 
(5 per cage) under 12 h light/dark cycles, with food 
and drinking provided ad libitum. Tumor growth was 
measured daily by caliper and calculated according to the 
equation (L × W2)/2, where L = tumor length, W = tumor 
width. When the tumor reached a volume of 100 mm3 
(day 7 after injection), the mice were randomized into 
8 groups (10 animals/group) and treated on days 0, 6 and 
12 after the randomization as it follows: 1) control group, 
treated with 0.1 ml saline solution intravenously (i.v.); 2) 
doxorubicin group, treated with 5 mg/kg doxorubicin i.v.; 3) 
tariquidar group, treated with 5 mg/kg tariquidar per os; 4) 
C1 19 group, treated with 19 ng/kg compound 1 (in 0.1 ml 
saline solution; final concentration: 10 nM) intratumorally; 
5) C1 1900 group, treated with 1900 ng/kg compound 
1 (in 0.1 ml saline solution; final concentration: 1 µM) 
intratumorally; 6) doxorubicin + tariquidar group, treated 
with 5 mg/kg doxorubicin i.v. and 5 mg/kg tariquidar per 
os; 7) doxorubicin + C1 19 group, treated with 5 mg/kg 
doxorubicin i.v. and 19 ng/kg compound 1 intratumorally; 
8) doxorubicin + C1 1900 group, treated with 5 mg/kg 
doxorubicin i.v. and 1900 ng/kg compound 1 intratumorally. 
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Tumor volumes were monitored daily by caliper and 
animals were euthanized by injecting zolazepam (0.2 ml/
kg) and xylazine (16 mg/kg) intramuscle (i.m.) at day 18. 
Tumors were excised and photographed immediately after 
mice sacrifice. The hematochemical parameters lactate 
dehydrogenase (LDH), aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), alkaline phosphatase (AP), 
creatinine, CPK were measured on 0.5 ml of blood collected 
immediately after mice sacrifice, using the respective kits 
from Beckman Coulter Inc. (Miami, FL). Animal care and 
experimental procedures were approved by the Bio-Ethical 
Committee of the Italian Ministry of Health (#122/2015-PR).
Pharmacokinetics
Plasma stability (mouse) and liver microsome 
metabolic stability (mouse) were measured by the 
Biopharmacy Laboratory, Shanghai Institute of Materia 
Medica, Chinese Academy of Sciences.
Statistical analysis
All data in the text and figures are provided as 
means ± SD. The results were analyzed by a one-way 
analysis of variance (ANOVA) and Tukey’s test, using 
Statistical Package for Social Science (SPSS) software (IBM 
SPSS Statistics v.19). p < 0.05 was considered significant.
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